Page 1

teva Revenues of $ 3.9 billion GAAP diluted EPS of $ 0.19 Non - GAAP diluted EPS of $ 0.59 Cash flow generated from operating activities of $ 218 million Free cash flow of $ 625 million IR Contacts 2021 revenue outlook revised lower to reflect ongoing impact of COVID - 19 ; all other key components reaffirmed : O PR Contacts O TEVA REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS O O Tel Aviv , July 28 , 2021 - Teva Pharmaceutical Industries Ltd. ( NYSE and TASE : TEVA ) today reported results for the quarter ended June 30 , 2021 . Net revenues of $ 16.0 - $ 16.4 billion vs. previous range of $ 16.4 - $ 16.8 billion Adjusted EBITDA of $ 4.8 - $ 5.1 billion EPS of $ 2.50 - $ 2.70 Free cash flow of $ 2.0 - $ 2.3 billion Mr. Kåre Schultz , Teva's President and CEO , said , " We have performed well in the second quarter , improving our profitability and free cash flow generation . This allowed us to reduce our net debt by an additional $ 500 million to $ 22.7 billion , once again demonstrating our commitment to and confidence in our long - term goals . Among our growth drivers , AUSTEDO® sales increased compared to the second quarter of last year , AJOVY® net sales have grown to $ 70 million worldwide , and our biosimilar TruximaⓇ continues to increase its U.S. market share , reaching 25 % . " Mr. Schultz continued , " Throughout the pandemic we remain committed to serving patients , maintaining our operations and delivering quality affordable medicines . Due to the effects of the pandemic , we have lowered our 2021 revenue outlook , while reaffirming our earnings and cash flow guidance . " Second Quarter 2021 Consolidated Results Revenues in the second quarter of 2021 were $ 3,910 million , an increase of 1 % or a decrease of 2 % in local currency terms , compared to the second quarter of 2020. This decrease was mainly due to lower revenues in our North America segment , mainly related to COPAXONEⓇ and Anda , partially offset by positive foreign currency impacts as well as higher revenues from generic products , OTC , AJOVY and COPAXONE in our Europe United States United States Israel Kevin C. Mannix Yael Ashman Kelley Dougherty Yonatan Beker ( 215 ) 591-8912 972 ( 3 ) 914-8262 ( 973 ) 832-2810 972 ( 54 ) 888 5898